for Journals by Title or ISSN
for Articles by Keywords
Journal Cover The Medical Letter
  [SJR: 0.314]   [H-I: 16]   [9 followers]  Follow
   Full-text available via subscription Subscription journal
   ISSN (Print) 0025-732X - ISSN (Online) 1523-2859
   Published by The Medical Letter, Inc Homepage  [1 journal]
  • In Brief: Midostaurin (Rydapt) for AML and Advanced Systemic Mastocytosis
           (online only)
    • Authors: admin
      Abstract: Date:  August 14, 2017 Issue #:  1527 Summary:  The FDA has approved the oral multikinase inhibitor midostaurin (Rydapt – Novartis) for first-line treatment, in addition to standard chemotherapy, of adults with FLT3 (fms-like tyrosine kinase 3) mutation-positive acute myeloid leukemia (AML). About 30% of patients with AML have FLT3 mutations. Midostaurin is also approved as a single agent for treatment of adults with aggressive systemic mastocytosis, systemic mastocytosis with associated hematological neoplasm, or mast-cell leukemia. In mastocytosis, midostaurin targets mutant c-KIT, not FLT3.

      In a randomized, double-blind trial, 717 adults 18-59 years old with newly diagnosed FLT3-mutated AML were treated with midostaurin (50 mg twice daily on days 8-21 of each 28-day cycle) or placebo in addition to standard chemotherapy (induction therapy with cytarabine and daunorubicin and consolidation therapy with high-dose cytarabine), followed by up to 12 additional maintenance cycles of midostaurin or placebo. More than half of the patients (57%) stopped treatment and underwent hematopoietic stem-cell transplantation during the trial. Median event-free survival was 8.2 months with midostaurin compared to 3.0 months with placebo, a significant difference. Median overall survival after a median follow-up of 59 months was significantly longer with midostaurin than with placebo (hazard ratio 0.78). The 4-year overall survival rate was 51.4% with midostaurin and 44.3% with placebo.1 Common adverse effects reported in the midostaurin plus chemotherapy group at a rate at least 2% higher than in the placebo plus chemotherapy arm included febrile neutropenia (83% vs 81%), nausea (83% vs 70%), vomiting (61% vs 53%), and mucositis (66% vs 62%). There were no differences between the two groups in the rates of severe (≥grade 3) adverse events.

      A single-arm, phase 2 study of midostaurin (100 mg twice daily in 4-week continuous cycles) included 89 adults with advanced systemic mastocytosis (16 had mast-cell leukemia) and evidence of organ damage. The overall response rate was 60%, and 45% of patients had a major response (complete resolution of at least one type of mastocytosis-related organ damage). The median duration of response was 24.1 months. Treatment with midostaurin also decreased splenomegaly and bone marrow mastcell burden. Median progression-free survival was 14.1 months and median overall survival was 28.7 months (9.4 months in patients with mast-cell leukemia). The most common adverse effects of midostaurin were nausea, vomiting, and diarrhea. New or worsening grade 3 or 4 neutropenia, anemia, and thrombocytopenia occurred in >20% of patients.2

      Rydapt is available in 25-mg capsules. For patients with AML, a 4-week treatment cycle (50 mg twice daily on days 8-21) costs $7495. For patients with advanced systemic mastocytosis, 4 weeks of treatment at 100 mg twice daily costs $29,980.3

      RM Stone et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med 2017 Jun 23 (epub).
      J Gotlib et al. Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J Med 2016; 374:2530.
      Approximate WAC. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource®Monthly. July 5, 2017. Reprinted with permission by First Databank, Inc. All rights reserved. ©2017.

      Download complete U.S. English article

      PubDate: Mon, 07 Aug 2017 19:06:01 +000
  • Olaratumab (Lartruvo) for Soft-Tissue Sarcoma (online only)
    • Authors: admin
      Abstract: Date:  August 14, 2017 Issue #:  1527 Summary:  Olaratumab (Lartruvo – Lilly), a platelet-derived growthfactor receptor alpha (PDGFR-α) blocking monoclonalantibody, has received accelerated approval from theFDA for use in combination with the anthracyclinedoxorubicin for first-line treatment of adults withsoft-tissue sarcoma histologic subtypes consideredsusceptible to anthracyclines. Approval is limited tolocally advanced or metastatic soft-tissue sarcomasthat are not amenable to curative radiotherapy orsurgery, and is contingent on verification of clinicalbenefit in a confirmatory phase 3 trial.
      PubDate: Mon, 07 Aug 2017 18:50:59 +000
  • Cardiovascular Effects of Some Antidiabetic Drugs
    • Authors: admin
      Abstract: Date:  August 14, 2017 Issue #:  1527 Summary:  For many years, the goal of drug therapy for mostpatients with type 2 diabetes has been to achieveand maintain an A1C of <7%. Achieving that goalcan prevent microvascular complications (diabeticretinopathy, nephropathy, neuropathy), but whether itprevents macrovascular complications (myocardialinfarction [MI], stroke) has been less clear. The FDAnow requires that cardiovascular safety studies beperformed for all new drugs for type 2 diabetes.1Recent findings that some of the newer second-linedrugs for type 2 diabetes have cardiovascular benefitshave led to new interest in the cardiovascular efficacyand safety of all antidiabetic drugs.
      PubDate: Wed, 12 Jul 2017 11:26:39 +000
  • Sarilumab (Kevzara) for Rheumatoid Arthritis
    • Authors: admin
      Abstract: Date:  August 14, 2017 Issue #:  1527 Summary:  The FDA has approved the interleukin (IL)-6 inhibitorsarilumab (Kevzara – Sanofi) for second-linetreatment of adults with moderately to severelyactive rheumatoid arthritis (RA). It is the second IL-6inhibitor to be approved for this indication; tocilizumab(Actemra) was approved earlier.
      PubDate: Wed, 12 Jul 2017 11:25:56 +000
  • Safety of Long-Term PPI Use
    • Authors: admin
      Abstract: Date:  August 14, 2017 Issue #:  1527 Summary:  Proton pump inhibitors (PPIs), which are used fortreatment of gastroesophageal reflux disease (GERD)and for prevention of upper gastrointestinal adverseeffects caused by NSAIDs and aspirin, are one ofthe most commonly prescribed classes of drugs inthe US. All PPIs are similarly effective and generallywell tolerated, but their long-term use has beenassociated with a number of safety concerns. Recommendations addressing these concerns haverecently been published.
      PubDate: Wed, 28 Jun 2017 12:16:29 +000
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
Home (Search)
Subjects A-Z
Publishers A-Z
Your IP address:
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-2016